AKTX Akari Therapeutics Plc

2.01
+0.01  (+1%)
Previous Close 2
Open 2.01
Price To Book -33.5
Market Cap 57,745,200
Shares 28,728,955
Volume 241,451
Short Ratio
Av. Daily Volume 181,979
Stock charts supplied by TradingView

NewsSee all news

  1. Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid

    NEW YORK and LONDON, May 21, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the

  2. Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series

    NEW YORK and LONDON, May 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  3. Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

    Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically significant reduction in Bullous Pemphigoid

  4. Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

    Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date - Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid and significant improvement in symptoms with a mean 63%

  5. Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement

    NEW YORK and LONDON, March 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim data January 10, 2020 noted all patients achieved the primary endpoint of transfusion independence. Further data due at EHA June 11-14, 2020.
Nomacopan - CAPSTONE (EHA)
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 enrolment has paused due to COVID-19.
Nomacopan
Atopic keratoconjunctivitis
Phase 2 trial met primary endpoint - May 1, 2020.
Nomacopan (Coversin)
Bullous Pemphigoid
Phase 3 trial initiation announced December 23, 2019.
Nomacopan
Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)

Latest News

  1. Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid

    NEW YORK and LONDON, May 21, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the

  2. Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series

    NEW YORK and LONDON, May 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  3. Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

    Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically significant reduction in Bullous Pemphigoid

  4. Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

    Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date - Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid and significant improvement in symptoms with a mean 63%

  5. Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement

    NEW YORK and LONDON, March 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  6. Akari Therapeutics, Plc Announces Private Placement

    NEW YORK and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  7. Rexgenero Appoints David Horn Solomon as Chairman

    Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), today announces that Dr. David Horn Solomon has been appointed to

  8. Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

     •The new data show PAS-nomacopan (the long acting form of Akari's lead drug, nomacopan) significantly reduced VEGF levels and retinal inflammation, both of which are associated with permanent damage in many

  9. Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study

    Phase III interim data on the first eight PNH patients who were all transfusion dependent at entry to the CAPSTONE trial show that all four patients randomized to nomacopan were transfusion independent for the first six

  10. Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND

    NEW YORK and LONDON, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  11. Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting

    Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from

  12. Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress

    -  New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration (FDA)-approved treatments for either disease. - 

  13. Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

    Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported findingThese new findings suggest that inhibition of both LTB4

  14. Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

    Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients– No reported drug-related serious adverse events– Achieved marked

  15. Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

    NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  16. Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

    NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  17. Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

    NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  18. Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co?

    NEW YORK, Aug. 30, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, BIG, CPB, and DIS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  19. Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

    NEW YORK and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where

  20. Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

    - Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019Phase I/II clinical study in patients with